CamAPS FX monitors glucose levels using data provided by a monitor and automatically adjusts the delivery of insulin via a pump, mimicking some of the functions of a healthy pancreas to stabilise glucose levels. It was developed by CamDiab at the University of Cambridge.

CamAPS FX is an artificial pancreas app which aims to help manage glucose levels in people with type 1 diabetes, aged one year and older, using a hybrid closed-loop approach.

The user has the option of easing off or boosting therapy as physiological demands require, such as during exercise. The app runs on a standard Android smartphone and feeds data to the cloud so that health care professionals and loved ones including parents can see their children’s levels at any time on their phones.

Developed by CamDiab at the University of Cambridge trials have shown a significant increase in glucose time in range and※improved quality of life, as well as a reduction in time spent in hypoglycaemia and hyperglycaemia. An Eastern AHSN commissioned health economic assessment also demonstrated a potential cost saving of £3.2m per year for healthcare in the UK. We are now supporting the roll out of this innovation across the NHS.

Visit the CamDiab website now.

Dr Louise Jopling Eastern AHSN Commercial Director
Get in touch

Find out more about using this app by contacting Dr Louise Jopling, Commercial Director at [email protected].

The challenge of new

Prof Roman Hovorka, professor of metabolic technology at the University of Cambridge, shares his experience navigating the innovation journey.

Read the article now…

Share your idea

Do you have a great idea that could make a positive health impact?

Get involved